Want to see BNTC full AI Analyst Report?
Top Page
Benitec Biopharma
(NASDAQ:BNTC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$9.00
▼(-30.88% Downside)
Action:Reiterated
Date:10/21/26
The score is primarily held down by weak financial performance (pre-revenue with widening losses and ongoing cash burn) and bearish technical conditions (below key moving averages with negative MACD). Corporate events provide some offset via positive regulatory momentum for BB-301, but valuation metrics remain constrained by losses and the lack of a dividend.
Positive Factors
Low Leverage
Very low leverage gives Benitec greater financial flexibility while it funds development programs, because limited debt reduces fixed repayment and interest burdens. The expanded equity base also provides a stronger capital foundation for continuing operations and pursuing clinical milestones.
Negative Factors
Pre-Revenue Business
The absence of meaningful revenue leaves Benitec dependent on research progress and future commercialization rather than established operating income. This limits earnings visibility and means the company cannot yet demonstrate recurring customer demand or validate its business model through product sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage gives Benitec greater financial flexibility while it funds development programs, because limited debt reduces fixed repayment and interest burdens. The expanded equity base also provides a stronger capital foundation for continuing operations and pursuing clinical milestones.
Read all positive factors
Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$301.79M
Dividend Yield0.12%
Average Volume (3M)199.24K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth14.04%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.98
Shares Outstanding34,889,313
10 Day Avg. Volume184,804
30 Day Avg. Volume199,237
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.52
Price to Sales (P/S)0.00
P/FCF Ratio-37.48
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-584.56
Enterprise Value/Ebitda-5.54
Forecast
1Y Price Target
$22.00Price Target Upside68.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Benitec Biopharma Business Overview & Revenue Model
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines...
Benitec Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 75.00K | 73.00K |
| Gross Profit | -481.00K | -396.00K | -343.00K | 75.00K | 64.00K |
| EBITDA | -50.71M | -41.37M | -22.15M | -18.70M | -17.78M |
| Net Income | -45.55M | -37.92M | -21.75M | -19.56M | -18.21M |
Balance Sheet | |||||
| Total Assets | 182.62M | 99.59M | 52.21M | 4.46M | 5.97M |
| Cash, Cash Equivalents and Short-Term Investments | 179.97M | 97.74M | 50.87M | 2.48M | 4.06M |
| Total Debt | 762.00K | 849.00K | 284.00K | 559.00K | 811.00K |
| Total Liabilities | 5.61M | 2.30M | 4.96M | 4.26M | 3.09M |
| Stockholders Equity | 177.01M | 97.30M | 47.25M | 202.00K | 2.88M |
Cash Flow | |||||
| Free Cash Flow | -16.62M | -23.61M | -19.58M | -18.01M | -15.91M |
| Operating Cash Flow | -16.52M | -23.59M | -19.40M | -18.01M | -15.90M |
| Investing Cash Flow | -105.00K | -18.00K | -179.00K | -1.00K | -13.00K |
| Financing Cash Flow | 98.98M | 70.48M | 68.03M | 16.02M | 0.00 |
Benitec Biopharma Technical Analysis
Negative
13.02
Price Trends
10.81
Negative
11.54
Negative
11.62
Negative
Market Momentum
-0.61
Negative
40.63
Neutral
50.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 8.96, above the 50-day MA of 10.81, and above the 200-day MA of 11.62, indicating a bearish trend. The MACD of -0.61 indicates Negative momentum. The RSI at 40.63 is Neutral, neither overbought nor oversold. The STOCH value of 50.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.
Benitec Biopharma Risk Analysis
Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Benitec Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $653.34M | -3.54 | -73.18% | ― | ― | 9.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $403.95M | 36.07 | -0.02% | ― | 125.12% | 98.69% | |
50 Neutral | $596.64M | -3.97 | -41.33% | ― | 278712.12% | 26.59% | |
46 Neutral | $301.79M | -8.83 | -28.41% | 0.12% | ― | 14.04% | |
45 Neutral | $12.54M | -0.34 | -145.40% | ― | -100.00% | 82.57% | |
45 Neutral | $251.38M | -14.31 | -5.76% | ― | ― | 93.45% |
* Healthcare Sector Average
BNTC
Benitec Biopharma
8.65
-7.05
-44.90%
TVRD
Tvardi Therapeutics
0.94
-3.93
-80.70%
ASMB
Assembly Biosciences
19.84
-9.96
-33.42%
RCKT
Rocket Pharmaceuticals
2.29
-1.65
-41.88%
FDMT
4D Molecular Therapeutics
10.80
-1.47
-11.98%
AURA
Aura Biosciences Inc
6.30
0.20
3.28%
Benitec Biopharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Benitec advances BB-301 gene therapy after FDA feedback
Positive
Oct 5, 2026
On October 5, 2026, Benitec Biopharma reported that the U.S. Food and Drug Administration provided formal feedback following a Type C meeting held in the third quarter of 2026 regarding the pivotal study of BB-301, its investigational gene therapy...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.